These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30429374)

  • 1. Tyro3 is a podocyte protective factor in glomerular disease.
    Zhong F; Chen Z; Zhang L; Xie Y; Nair V; Ju W; Kretzler M; Nelson RG; Li Z; Chen H; Wang Y; Zhang A; Lee K; Liu Z; He JC
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TYRO3 agonist as therapy for glomerular disease.
    Zhong F; Cai H; Fu J; Sun Z; Li Z; Bauman D; Wang L; Das B; Lee K; He JC
    JCI Insight; 2023 Jan; 8(1):. PubMed ID: 36454644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein S Protects against Podocyte Injury in Diabetic Nephropathy.
    Zhong F; Chen H; Xie Y; Azeloglu EU; Wei C; Zhang W; Li Z; Chuang PY; Jim B; Li H; Elmastour F; Riyad JM; Weber T; Chen H; Wang Y; Zhang A; Jia W; Lee K; He JC
    J Am Soc Nephrol; 2018 May; 29(5):1397-1410. PubMed ID: 29511111
    [No Abstract]   [Full Text] [Related]  

  • 4. TYRO3 protects podocyte via JNK/c-jun-P53 pathway.
    Zhang L; Jiang S; Shi J; Xu X; Wang L; Zhai X; Hou Q; Qin W; Chen Z
    Arch Biochem Biophys; 2023 May; 739():109578. PubMed ID: 36948351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role and Mechanisms of Tyro3 in Podocyte Biology and Glomerular Disease.
    Min L; Chen Y; Zhong F; Gu L; Lee K; He JC
    Kidney Dis (Basel); 2024 Oct; 10(5):398-406. PubMed ID: 39430290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression.
    Chen A; Feng Y; Lai H; Ju W; Li Z; Li Y; Wang A; Hong Q; Zhong F; Wei C; Fu J; Guan T; Liu B; Kretzler M; Lee K; He JC
    J Clin Invest; 2020 Oct; 130(10):5523-5535. PubMed ID: 32634130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PCSK9 in glomerular lipid accumulation and renal injury in diabetic kidney disease.
    Wu M; Yoon CY; Park J; Kim G; Nam BY; Kim S; Park JT; Han SH; Kang SW; Yoo TH
    Diabetologia; 2024 Sep; 67(9):1980-1997. PubMed ID: 38879617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
    He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
    Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.
    Lay AC; Hale LJ; Stowell-Connolly H; Pope RJP; Nair V; Ju W; Marquez E; Rollason R; Hurcombe JA; Hayes B; Roberts T; Gillam L; Allington J; Nelson RG; Kretzler M; Holly JMP; Perks CM; McArdle CA; Welsh GI; Coward RJM
    Diabetologia; 2021 Jul; 64(7):1690-1702. PubMed ID: 33758952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular Endothelial Mitochondrial Dysfunction Is Essential and Characteristic of Diabetic Kidney Disease Susceptibility.
    Qi H; Casalena G; Shi S; Yu L; Ebefors K; Sun Y; Zhang W; D'Agati V; Schlondorff D; Haraldsson B; Böttinger E; Daehn I
    Diabetes; 2017 Mar; 66(3):763-778. PubMed ID: 27899487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease.
    Liu XQ; Jiang L; Li YY; Huang YB; Hu XR; Zhu W; Wang X; Wu YG; Meng XM; Qi XM
    Acta Pharmacol Sin; 2022 Jan; 43(1):96-110. PubMed ID: 34253875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-
    Hong Q; Zhang L; Fu J; Verghese DA; Chauhan K; Nadkarni GN; Li Z; Ju W; Kretzler M; Cai GY; Chen XM; D'Agati VD; Coca SG; Schlondorff D; He JC; Lee K
    J Am Soc Nephrol; 2019 Apr; 30(4):546-562. PubMed ID: 30858225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RIPK3 causes mitochondrial dysfunction and albuminuria in diabetic podocytopathy through PGAM5-Drp1 signaling.
    Kang JS; Cho NJ; Lee SW; Lee JG; Lee JH; Yi J; Choi MS; Park S; Gil HW; Oh JC; Son SS; Park MJ; Moon JS; Lee D; Kim SY; Yang SH; Kim SS; Lee ES; Chung CH; Park J; Lee EY
    Metabolism; 2024 Oct; 159():155982. PubMed ID: 39089491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus.
    Srivastava SP; Zhou H; Setia O; Dardik A; Fernandez-Hernando C; Goodwin J
    J Am Heart Assoc; 2021 Aug; 10(15):e019437. PubMed ID: 34308664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRMT1 mediates podocyte injury and glomerular fibrosis through phosphorylation of ERK pathway.
    Zhu Y
    Biochem Biophys Res Commun; 2018 Jan; 495(1):828-838. PubMed ID: 29129692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-associated nephropathy: experimental models.
    Avila-Casado C; Fortoul TI; Chugh SS
    Contrib Nephrol; 2011; 169():270-285. PubMed ID: 21252526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
    Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
    Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fn14 in podocytes and proteinuric kidney disease.
    Sanchez-Niño MD; Poveda J; Sanz AB; Mezzano S; Carrasco S; Fernandez-Fernandez B; Burkly LC; Nair V; Kretzler M; Hodgin JB; Ruiz-Ortega M; Selgas R; Egido J; Ortiz A
    Biochim Biophys Acta; 2013 Dec; 1832(12):2232-43. PubMed ID: 23999007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMPK mediates regulation of glomerular volume and podocyte survival.
    Banu K; Lin Q; Basgen JM; Planoutene M; Wei C; Reghuvaran AC; Tian X; Shi H; Garzon F; Garzia A; Chun N; Cumpelik A; Santeusanio AD; Zhang W; Das B; Salem F; Li L; Ishibe S; Cantley LG; Kaufman L; Lemley KV; Ni Z; He JC; Murphy B; Menon MC
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34473647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury.
    Feng Y; Sun Z; Fu J; Zhong F; Zhang W; Wei C; Chen A; Liu BC; He JC; Lee K
    Kidney Int; 2024 Jul; 106(1):50-66. PubMed ID: 38697478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.